Eden Research plc
LSE : EDE

October 31, 2011 03:00 ET

Positive nematode trial results under Certis agreement

                                                                                     31st October 2011
                                                                             GB0001646941/GBP/PLUS-exn
                                                   
                                           EDEN RESEARCH PLC
                                       ("Eden" or the "Company")

                        Positive nematode trial results under Certis agreement
                                                   
                                                   
*       Positive  trial  results  for  Eden's nematode product  - similar performance  to   a  leading
        traditional agrochemical

*       Results  also show less crop damage in the absence of pests or disease compared with a leading
        traditional agrochemical
   
Eden  Research  plc,  the agrochemical and encapsulation development company, is pleased  to  announce
positive interim trial results from the evaluation of its nematode product under the exclusive  option
agreement that Eden entered into with Certis Europe BV ("Certis") in 2010.

The  purpose  of  these trials was to prove the efficacy and viability of Eden's nematode  product  to
enable  Certis  to  decide  whether  to exercise its option and  to  provide  data  for  the  European
registration process required to register and sell the product.

The  first  set  of studies show good efficacy for Eden's nematode product and similar  results  to  a
leading  traditional agrochemical competitor product, against which Eden's product was  compared.  The
trials  were  undertaken to assess control of Root Knot nematodes (Meloidogyne incognita) in  tomatoes
and peppers, a major pest in these crops grown in protected or field crop situations.

In  addition,  Eden's product demonstrated less crop damage, in the absence of any pests  or  disease,
when  compared with the leading traditional agrochemical competitor product, confirming  results  from
previous trials.

The  option  agreement gives Certis the exclusive right to enter into a licence agreement  for  Eden's
nematode  product  for Europe, Asia, Africa, Oceania and the Middle East and expires  on  31  December
2011. In the event that Certis exercises its option, a minimum licence fee of USD 0.9m becomes payable
to Eden, with royalties on net sales thereafter.

The second and final set of trial results is due in mid-December 2011.

Clive Newitt, Managing Director of Eden, said, "These results are positive for Eden and  pave the  way
for  a  long-term  relationship  with Certis, one of the leaders in  nematode  control  through  their
CleanStart programme. The results are also a good indicator for our other partners who have rights  to
the nematode product in other parts of the world.

We  are  eagerly anticipating the second set of trial results and will keep shareholders  informed  of
progress."


The Directors of Eden are responsible for the contents of this announcement.


Enquiries:

Eden Research plc                                                                  01993 862761
Clive Newitt, Managing Director

St Helens Capital Partners LLP                                                     020 7368 6959
Mark Anwyl



Notes:

Eden  has developed a terpene-based encapsulation technology which uses yeast cells to deliver a  slow
release of natural compounds for agricultural and non-agricultural uses.

Terpenes  are  natural  compounds which function as defence mechanisms in many plant  groups  and  are
released in response to infection, attack by pests, stress or mechanical injury. Terpenes are  already
widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically,  terpenes  have  had  limited commercial use in the agrochemical  sector  due  to  their
volatility,  phytotoxicity and poor solubility. Eden's platform encapsulation  technology  provides  a
unique,  environmentally  friendly solution to these problems and  enables  terpenes  to  be  used  as
effective, low-risk agrochemicals.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School
("UMMS")  recently,  provides  significant additional benefits to the original  system  as  it  allows
release to be controlled by environmental factors rather than relying solely upon the chemistry of the
substances  used. This means that there is more control over the timing of the release of  the  active
compound  being  carried allowing for further reduction in chemicals applied whilst  ensuring  maximum
effectiveness.

The  UMMS  license  also  significantly expands the potential use  of  the  Eden  technology  in  non-
agricultural applications such as health and beauty, cosmetics and animal health.


For more information about Eden, please visit www.edenresearch.com

Contact Information

  • Eden Research plc